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AbstrACt
Introduction Overtreatment of localised prostate cancer 
is substantial despite increased use of active surveillance. 
No randomised trials help define how to monitor patients 
or when to initiate treatment with curative intent.
Methods and analysis A randomised, multicentre, 
intervention trial designed to evaluate the safety of an 
MRI-based active surveillance protocol, with standardised 
triggers for repeated biopsies and radical treatment. The 
aim is to reduce overtreatment of prostate cancer. 2000 
men will be randomly allocated to either surveillance 
according to current practice or to standardised triggers 
at centres in Sweden, Norway, Finland and the UK. Men 
diagnosed in the past 12 months with prostate cancer, 
≤T2a, prostate-specific antigen (PSA) <15 ng/mL, PSA 
density ≤0.2 ng/mL/cc, any International Society of 
Urological Pathology (ISUP) grade 1 are eligible. Men 
with ISUP grade 2 in <30% of cores on systematic 
biopsy and <10 mm cancer in one core on systematic 
or targeted biopsy are also eligible. Men diagnosed on 
systematic biopsy should have an MRI and targeted 
biopsies against Prostate Imaging and Reporting Data 
System V.2 3–5 lesions before inclusion. Identical follow-
up in the two study arms: biannual PSA testing, yearly 
clinical examination and MRI every second year. In 
the experimental arm, standardised triggers based on 
MRI and PSA density elicit repeated biopsies. MRI and 
histopathological progression trigger radical treatment. 
Primary outcome measure is progression-free survival. 
Secondary outcome measures are cumulative incidence 
of metastatic disease, treatments with curative intent, 
pT3-4 at radical prostatectomy, switch to watchful waiting, 
prostate cancer mortality and quality of life. Inclusion 
started in October 2016 and in October 2018; 275 patients 
have been enrolled.
Ethics and dissemination Ethical approval was obtained 
in each participating country. Results for the primary 
and secondary outcome measures will be submitted for 
publication in peer-reviewed journals.
trial registration number NCT02914873.
IntroduCtIon
Following the introduction of prostate-spe-
cific antigen (PSA) testing in the late 1980s, 
the incidence of prostate cancer increased 
dramatically in many countries.1 Widespread 
PSA testing led to a downward stage migra-
tion, with a growing proportion of small and 
well-differentiated cancers with low malig-
nant potential even if left untreated.2
Although overdiagnosis of prostate 
cancers has been documented on a group 
level,2 currently it is not possible to know if 
an individual man with prostate cancer will 
experience progression to lethal disease or 
not. As a consequence, many men unneces-
sarily undergo radical treatment. To reduce 
overtreatment and its side effects, without 
jeopardising the potential benefit of radical 
treatment, active surveillance with selective, 
delayed therapy with curative intent was 
developed in the late 1990s.3
In active surveillance, treatment with 
curative intent is initiated when and if inves-
tigations indicate progressive cancer. In 
watchful waiting only palliative treatment 
is initiated at symptoms. Several national 
guidelines recommend active surveillance 
for most low-risk cancers and selected favour-
able intermediate-risk cancers.4 Different 
criteria are used to trigger radical treat-
ment, but many patients are treated with 
curative intent without objective signs of 
disease progression.5 Although multiple 
active surveillance cohorts show low rates of 
strengths and limitations of this study
 ► The randomised design reduces chances of ob-
served outcome being influenced by confounding 
factors.
 ► The trial size will allow quantifying clinically relevant 
end points with reasonable statistical precision.
 ► International multicentre study making results more 
generalisabe.
 ► Limitations include long follow-up that has to be un-
dertaken to assess tumour progression.
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disease progression,6 no randomised trials help define 
which patients are suitable for active surveillance, how to 
monitor them or when to initiate treatment with curative 
intent. To fill some of these evidence gaps and reduce 
both overtreatment and undertreatment, the Scandi-
navian Prostate Cancer Group (SPCG) is promoting a 
multinational randomised trial, Prostate Cancer Active 
Surveillance Trigger trial (PCASTt/SPCG-17), in which 
standardised triggers for repeat biopsies and initiation of 
treatment with curative intent, is compared with current 
clinical practice for active surveillance of low-risk and 
favourable intermediate-risk prostate cancer.
Areas of uncertainty
Active surveillance or immediate treatment with curative intent
None of three randomised trials has shown substan-
tial survival benefit of radical treatment compared with 
watchful waiting or active monitoring in men with low-risk 
prostate cancer.7–9 The SPCG-4 trial began in 1989, that 
is, before the PSA era, and included primarily men with 
palpable tumours. In this trial, radical prostatectomy 
resulted in a 3.8% (95% CI −4.6 to 12.2) lower prostate 
cancer mortality in men with low-risk cancer, compared 
with watchful waiting, after 18 years of follow-up.7 In the 
PIVOT trial (Prostate Cancer Intervention Versus Obser-
vation Trial) including predominantly men with PSA 
detected localised cancer, there was a 4% absolute reduc-
tion of prostate cancer-specific mortality (95% CI −0.2 to 
8.3) after radical prostatectomy, compared with observa-
tion, after nearly 20 years of follow-up. Events were few in 
the subgroup analysis, ensuing low statistical precision.8 
In ProtecT, only men with PSA-detected tumours were 
included. After 10 years of follow-up, prostate cancer-spe-
cific survival was similar in the three treatment groups: 
98.8% (95% CI 98.4 to 99.5) after initial active moni-
toring, 99.0% (95% CI 97.2 to 99.6) in men allocated to 
radical prostatectomy and 99.6% (95% CI 98.4 to 99.9) in 
men allocated to radiotherapy, but progression to meta-
static disease was less common after treatment with cura-
tive intent.9
Criteria for active surveillance
Most published active surveillance protocols include men 
with low-risk disease (International Society of Urolog-
ical Pathology (ISUP) grade 1 (Gleason score 3+3=6), 
T1c-T2a and PSA <10 ng/mL), but some include inter-
mediate-risk disease (ISUP grade 2 (Gleason score 
3+4=7), T1c-T2 and PSA 10–20 ng/mL).6 ProtecT, the 
only randomised trial addressing the question of active 
monitoring versus curative treatment, included all local-
ised risk groups but predominantly low risk. They found a 
higher risk of progression to metastases with active moni-
toring compared with radical treatment, after 10 years.9 
However, active monitoring in their protocol consisted of 
repeated PSA testing but apart from that was not specifi-
cally regulated.
Follow-up during active surveillance
Active surveillance protocols differ, but they typically 
include repeated digital rectal examinations, PSA testing 
and systematic, transrectal biopsies. Interpretation of 
digital rectal examination is subjective and cannot detect 
tumours in the anterior part of the prostate, which limit its 
usefulness.10 PSA values fluctuate over time,11 and raising 
values may reflect inflammation or progression of benign 
hyperplasia, rather than tumour progression. Systematic 
biopsies can easily miss small multifocal cancers and large 
tumours in the anterior prostate. Histopathological evalu-
ation of the specimen shows considerable interindividual 
variation between pathologists.12
Repeated biopsy and conversion to radical treatment
In Sweden, 30%–40% of men managed by active surveil-
lance receive treatment with curative intent within 5 years 
after diagnosis.13 In a nationwide study, active surveillance 
was discontinued because of ‘patient preference’ in 20%, 
by PSA progression in 52% and by biopsy progression in 
24% of the men.13 In the PRIAS study (Prostate Cancer 
Research International Active Surveillance), about half of 
the men switched to curative treatment within 2.3 years.14 
Worry about whether the patient has an undetected high-
risk cancer, without objective signs of progression or 
high-risk cancer, may entail unnecessary repeated biop-
sies and treatment to accommodate the clinicians’ and 
the patients’ concerns. Conversely, digital rectal exam-
ination, PSA and systematic biopsies have low sensitivity 
to detect high-grade cancer.10–12 Hence, we do not know 
when repeated biopsies are required and when radical 
treatment is beneficial.
Magnetic resonance imaging
The use of MRI in the assessment of prostate cancer 
has increased. There is high level evidence that MRI 
has the ability to detect prostate cancer,15 16 but there 
is insufficient evidence on the benefit of repeated MRI 
during active surveillance.17 According to the PROMIS 
study (Prostate MR Imaging Study), MRI may reduce 
the proportion of men undergoing a prostate biopsy by 
25%, and the proportion of men diagnosed with clini-
cally insignificant cancer by 5%, at the cost of delaying 
the diagnosis of a clinically significant cancer (defined as 
presence of any ISUP grade ≥3 (Gleason score 4+3=7) or 
a maximum cancer core length involvement of 6 mm or 
more in any location) in 3% of the men.18 The negative 
predictive value of an unsuspicious MRI finding is high, 
and even higher when PSA density is low.19
The randomised PRECISION (Prostate Evaluation 
for Clinically Important Disease: Sampling Using Image 
Guidance or Not?) trial indicates that MRI with targeted 
biopsies has higher detection rate than systematic biop-
sies for ISUP grade ≥2 prostate cancer and reduces the 
detection of ISUP grade 1 cancer in biopsy-naïve patients 
with clinical suspicion of prostate cancer.20 In a retrospec-
tive review of repeated biopsies during active surveillance, 
MRI with targeted biopsies nearly doubled the detection 
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box 1 Inclusion criteria
 ► Adenocarcinoma of the prostate diagnosed within the past 12 
months.
 ► Tumour stage ≤T2a, NX, M0.
 ► PSA <15 ng/mL and PSA density ≤0.2 ng/mL/cc.
 ► Systematic biopsies with ≥10 cores (optional, if the diagnosis is 
based on MRI with targeted biopsies).
 ► MRI with targeted biopsies towards PI-RADS 3, 4 and 5 (according 
to PI-RADS V.2).
 ► ISUP grade 1 (any number of cores, any involvement).
 ► ISUP grade 2 in <3 cores (or <30% of cores if >10 systematic 
cores were taken) and <10 mm cancer in one core (systematic or 
targeted).
 ► Life expectancy ≥10 years (no upper age limit).
 ► Candidate for curative treatment (surgery or radiotherapy), if pro-
gression occurs.
 ► Signed written informed consent.
ISUP, International Society of Urological Pathology; PI-RADS, Prostate Imaging 
Reporting and Data System; PSA, prostate-specific antigen.
box 2 demands on participating centres
 ► Access to prostate MRI expertise. If the local competence is un-
certain, the national PI will organise external expertise for MRI 
evaluation.
 ► The MRI should follow European Society of Urogenital Radiology 
guidelines and include:
 – T1-weighted and T2-weighted images;
 – Diffusion-weighted images including apparent diffusion 
coefficient;
 – Dynamic contrast-enhanced imaging and magnetic resonance 
spectroscopy imaging are optional.
 ► The MR images should be reported according to PI-RADS V.2.
PI-RADS, Prostate Imaging Reporting and Data System.
of pathological progression compared with systematic 
biopsies.21 This is however questioned by a recent prospec-
tive trial that showed no increase in upgrading with addi-
tional targeted biopsies versus systematic biopsies alone.22
Active surveillance in intermediate-risk prostate cancer
The risk of cancer progression during active surveillance 
of patients with low-risk prostate cancer is low, but varies 
between studies, probably because of different inclusion 
criteria and indications for therapeutic intervention.6 
Active surveillance of intermediate-risk prostate cancer is 
debated, but it is supported by some data.23 The Sunny-
brook cohort—including men with low-risk and favour-
able intermediate-risk prostate cancer—showed a 2.8% 
progression to metastatic disease and 1.5% prostate 
cancer-specific mortality within 15 years,24 with a more 
favourable outcome for men with low-risk cancer.25 Eligi-
bility was not influenced by PSA density or number of 
positive cores, and MRI was not used. Based on findings 
that MRI with targeted biopsies has a higher detection 
rate than standard biopsies for ISUP grade ≥2 prostate 
cancer,20 one must assume that many intermediate-risk 
and high-risk tumours were undetected in this cohort. 
Despite this, the long-term cancer-specific survival was 
high.
the PCAstt/ sPCG-17 trial
Study design
The PCASTt/SPCG-17 is a multinational randomised trial 
comparing active surveillance using standardised triggers 
for repeated biopsy and radical treatment with current 
practice. The hypothesis is that standardised triggers will 
reduce overtreatment and adverse events and improve 
quality of life, without increasing disease progression or 
prostate cancer mortality.
Outcome measures
The primary end point is progression-free survival. 
Progression is defined as biochemical recurrence after 
treatment with curative intent or start of androgen depri-
vation therapy in previously untreated men. Following 
radical prostatectomy, biochemical recurrence is defined 
as two consecutive rising PSA values >0.2 ng/mL. After 
primary radiation therapy and radiation therapy with 
androgen deprivation therapy, the definition of biochem-
ical recurrence is any PSA increase 2 ng/mL higher than 
the PSA nadir value, regardless of the serum concentration 
of the nadir.26 Secondary end points are the cumulative 
incidence of pT3 tumours, distant metastasis, treatment 
with curative intent and switch to watchful waiting. Pros-
tate cancer death is the final end point at 10 years. Quali-
ty-of-life end points will be analysed separately.
Participants and participating centres
Eligible for inclusion are men with histopathological 
low-risk or favourable intermediate-risk adenocarcinoma 
of the prostate diagnosed within 12 months, who have 
not received any treatment and have at least 10 years’ 
expected lifetime. All men primarily diagnosed with 
prostate cancer from systematic biopsies should undergo 
MRI with biopsies targeted towards Prostate Imaging and 
Reporting Data System (PI-RADS) 3–5 lesions before 
inclusion. For men primarily diagnosed with prostate 
cancer following MRI with targeted biopsies, subsequent 
systematic biopsies are optional. Inclusion criteria are 
listed in box 1. Centres in Sweden, Finland, Norway and 
the UK will participate. Demands on participating centres 
are listed in box 2.
PCASTt/SPCG-17 aims to randomise 2000 patients 
in 4 years, which will give an 85% power to detect a 
1.3 percentage points progression-free survival differ-
ence between the study arms (two-sided α=0.05) under 
the assumption that 90% of the patients are managed 
per protocol according to randomisation. The progres-
sion-free survival in the current practice group 5 years 
after randomisation is assumed to be 98%, based on 
previous studies.24
Patient-reported outcome measures and follow-up
At inclusion and every second year during follow-up 
participants are requested to complete a study-specific 
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Figure 1 Basic follow-up. PSA, prostate-specific antigen; QoL, quality of life; SB, systematic biopsies; TB, targeted biopsies.
Table 1 Triggers for re-biopsies
Arm 1 Arm 2
According to current practice
(the urologists’ judgement)
I PSA density >0.2 ng/mL/cc (systematic biopsies)
  II   MRI progression in men with ISUP grade 1 cancer (targeted biopsies)
 ► ≥5 mm or more increase in size in any dimension of a measurable lesion (a 
measurable lesion is defined as ≥6 mm in longest diameter in any dimension in 
best-depicted MR sequence)
 ► Increase in PI-RADS score to 3, 4 or 5
 ► High suspicion of extracapsular extension or seminal vesicle invasion (level of 
suspicion to be 4 or 5 on Likert scale)
 ► A new lesion with PI-RADS score 3–5
  III   MRI progression in men with ISUP grade 2 cancer (targeted biopsies)
 ► ≥5 mm or more increase in size in any dimension of a measurable lesion (a 
measurable lesion is defined as ≥6 mm in longest diameter in any dimension in 
best-depicted MR sequence)
 ► A new lesion with PI-RADS 3–5
ISUP, International Society of Urological Pathology; PI-RADS, Prostate Imaging Reporting and Data System; PSA, prostate-specific antigen.
quality-of-life questionnaire including the Expanded 
Prostate cancer Index Composite -26,27 for separate qual-
ity-of-life analysis.
Basic follow-up is identical in both arms, with bian-
nual PSA testing, annual clinical examination and MRI 
scan every second year (figure 1). In the current practice 
arm, additional investigations are optional and it is up to 
the urologist to decide when it is time to repeat biopsies 
and initiate treatment with curative intent. In the exper-
imental arm, follow-up is according to schedule, biopsies 
are only taken if the standardised triggers are reached 
(table 1) and treatment with curative intent is only recom-
mended if standardised triggers for radical treatment are 
reached (table 2). At every follow-up, the patient is cate-
gorised as having no distant metastasis, suspected distant 
metastasis (according to PSA-level and/or symptoms) or 
verified distant metastasis (imaging or histopathology/
cytology).
Follow-up continues according to the protocol until 
initiation of treatment with curative intent, detection of 
metastasis, switch from active surveillance to watchful 
waiting or death of any cause. For men who discon-
tinue active surveillance, the follow-up and management 
continue according to standard clinical practice but with 
annual reporting in the study. In patients lost to follow-up, 
end points will be assessed through available registers in 
the participating countries.
Patient and public involvement
Patient experiences and priorities is important knowledge 
that may influence the definition of research questions. 
Patients were however not directly involved in designing 
this study, defining outcome measures, the recruitment 
to and conduct of the study. A summary of results will be 
available for all participants and will also be presented to 
patient organisations and the public.
Experience from first 2 years of inclusion
The first patient was included in October 2016 at Uppsala 
University Hospital, Sweden. In 2017, six additional 
Swedish centres began enrolment and three Norwegian 
centres started enrolling patients in 2018. Centres in 
Finland and the UK aim to start including patients later in 
2018. Characteristics of the first 275 randomised patients 
are displayed in table 3. Patients are stratified based on 
participating centre and Gleason score.
Ethics and dissemination
The first analysis of primary and secondary end points 
will take place 1 year after all men are included (and then 
every third year) and will be published in peer-reviewed 
journal.
dIsCussIon
The increasing use of active surveillance has reduced 
overtreatment of prostate cancer to some extent, but still 
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Table 3 Baseline characteristics for the first 275 included 
patients
n 139 (Arm 1) 136 (Arm 2)
Age (year, mean (SD)) 62 (6.2) 64 (6.2)
PSA (ng/mL, mean, (SD)) 5.1 (2.3) 5.8 (2.3)
PSA-D (ng/mL/cc, mean (SD)) 0.11 (0.04) 0.12 (0.04)
Clinical tumour stage (n (%))
  T1c 109 (78) 115 (85)
  T2a 29 (21) 21 (15)
  Unknown 1 (1) 0
Comorbidity (n (%))
  ASA 1 94 (68) 84 (62)
  ASA 2 40 (29) 52 (38)
  ASA 3 4 (3) 0
  Unknown 1 (1) 0
Family history of PCA (n (%))
  Yes 33 (24) 38 (28)
  No 102 (73) 95 (70)
  Unknown 4 (3) 3 (2)
MRI technique (n (%))
  1.5 T 20 (14) 16 (12)
  3 T 118 (85) 116 (85)
  Unknown 1 (1) 4 (3)
MRI findings (n (%))
  PI-RADS 1–2 76 (55) 55 (40)
  PI-RADS 3–5 63 (45) 81 (60)
ASA, American Society of Anesthesiologists classification; PCA, 
prostate cancer; PI-RADS, Prostate Imaging Reporting and Data 
System; PSA, prostate-specific antigen; n, sample size.
Table 2 Triggers for radical treatment
Arm 1 Arm 2
According to current 
practice
(the urologist’s judgement)
I MRI progression in lesions with confirmed Gleason pattern 4
 ► Increase in PI-RADS score to 4 or 5
 ► High suspicion of extracapsular extension or seminal vesicle invasion (level of 
suspicion to be 4 or 5 on the Likert scale)
  II Pathological progression
 ► Gleason pattern 5
 ► Primary Gleason pattern 4 in any core with ≥5 mm cancer
 ► ISUP grade 2 in ≥3 cores (or ≥30% of cores if >10 systematic cores), or ≥10 mm 
cancer in one core (systematic or targeted)
ISUP, International Society of Urological Pathology; PI-RADS, Prostate Imaging Reporting and Data System.
a large number of men are overtreated.2 Clearly, more 
patients should start on active surveillance, and fewer 
patients on active surveillance should convert to radical 
treatment.
Over the last decades, there has been a Gleason score/
ISUP grade inflation, partly due to the 2005 revision of 
the Gleason pattern definitions. The revision entailed 
that many patterns previously designated Gleason pattern 
3 are now reported as pattern 4 and that the Gleason 
score/ISUP grade on needle biopsies always includes the 
highest Gleason grade, even if it is just a minimal compo-
nent.28 Because long-term outcomes of active surveillance 
and watchful waiting are chiefly based on studies under-
taken before the 2005 revision, a substantial proportion 
of low-risk tumours in those studies would today be classi-
fied as intermediate risk. Despite this, they had excellent 
survival without treatment. These results and the changes 
in Gleason grading suggests that also men with favour-
able intermediate-risk prostate cancer should be offered 
active surveillance. This is supported by the fact that 
MRI with targeted biopsies detects favourable intermedi-
ate-risk tumours that standard biopsies do not detect.18 20 
Hence, if all men with intermediate-risk prostate cancer 
undergo immediate radical treatment, overtreatment 
would increase.
In PCASTt/SPCG-17, follow-up during active surveil-
lance is based on PSA testing and repeated MRI, not 
on repeated systematic biopsies. Prostate biopsies are 
uncomfortable and distressful. They cause bleeding, 
sometimes urinary retention and about 6% experience 
febrile infection and 1% develop sepsis.29 The incidence 
of serious infections is rising because of multidrug-re-
sistant bacteria.30 It is therefore desirable to reduce the 
number of biopsies during active surveillance. In the 
experimental arm of PCASTt/SPCG-17, biopsies are only 
performed when triggered which will likely reduce the 
number of biopsies. MRI with targeted biopsies detect at 
least as many histopathological intermediate-risk tumours 
as standard biopsies in biopsy-naïve men,20 21 suggesting 
that MRI with targeted biopsies is viable in a surveillance 
programme.
In PCASTt/SPCG-17, prespecified changes in MRI 
trigger targeted biopsies to assess histopathological 
progression. Since histopathological progression may 
occur without MRI changes, the protocol also stipu-
lates systematic biopsies if PSA density increases above 
prespecified limits (table 1). Radical treatment is trig-
gered by MRI findings suggesting progression of a known 
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ISUP grade 2 tumour and by biopsies showing more than 
a defined upper limit of Gleason pattern 4 or any Gleason 
pattern 5 (table 2).
The strengths of PCASTt/SPCG-17 include the 
randomised design and a trial size that will allow quanti-
fying clinically relevant end points with reasonable statis-
tical precision. A data monitoring and safety committee 
will oversee patient safety and the trial’s scientific 
integrity. The safety of the MRI-based follow-up will be 
regularly evaluated by comparing the outcome with a 
matched group of men managed by active surveillance 
in the Swedish SAMS study (Study of Active Monitoring 
in Sweden), who are on active surveillance based on 
systematic transrectal biopsies.31 During the long-term 
follow-up, new methods for monitoring and treatment 
might be introduced and applied in our patient cohort, 
obscuring the interpretation of the results. Furthermore, 
over time the triggers for repeated biopsies and treatment 
in the PCASTt/SPCG-17 trial’s standard treatment arm 
might become more similar to the management of the 
men in the experimental group. Although this will affect 
the trial’s ability to detect any difference between the two 
groups, the PCASTt/SPCG-17 experimental arm can still 
be used to assess the clinical safety and acceptability of 
a standardised protocol and provide prospective data 
on the performance of MRI as a monitoring tool—both 
aspects key to patient safety under active surveillance.
ConClusIon
PCASTt/SPCG-17 is a randomised trial that evaluates 
the safety of an MRI-based active surveillance protocol, 
comparing standardised triggers for repeat biopsies and 
curative treatment. If the protocol proves to be as safe 
as current clinical practice, its implementation could 
lead to a reduction of the number of biopsies, reduce 
overtreatment of prostate cancer without compromising 
the outcome of the patients in terms of morbidity and 
mortality.
Author affiliations
1Uppsala Universitet Institutionen for Kirurgiska Vetenskaper, Uppsala, Sweden
2Karolinska Institutet Department of Medical Epidemiology and Biostatistics, 
Stockholm, Sweden
3Department of Epidemiology, Harvard University T H Chan School of Public Health, 
Boston, Massachusetts, USA
4King’s College London Translational Oncology and Urology Research, London, UK
5University of Southern Australia Centre for Population Health Research, Adelaide, 
South Australia, Australia
6Department of Urology, Sankt Olavs Hospital Universitetssykehuset i Trondheim, 
Trondheim, Norway
7Department of Cancer Research and Molecular Medicine, NTNU—Norwegian 
University of Science and Technology, Trondheim, Norway
8Department of Urology, Goteborgs universitet Sahlgrenska Akademin, Goteborg, 
Sweden
9The Royal Mardsen Hospital, London, London, UK
10Department of Pathology, Karolinska Universitetssjukhuset, Stockholm, Sweden
11School of Cancer & Pharmaceutical Sciences, King's College London, London, UK
12Regional Cancer Centre Uppsala/Örebro, Uppsala, Sweden
13Division of Cancer Studies, King's College London School of Medicine, London, UK
14Helsinki University and Helsinki University Hospital, Helsinki, Finland
15Translational Oncology & Urology Offices, Kings College London, London, UK
16Radiology Department, Karolinska Universitetssjukhuset, Stockholm, Sweden
17Karolinska Institutet Department of Molecular Medicine and Surgery, Stockholm, 
Sweden
Acknowledgements The authors would like to thank the following contributors to 
the study: Monica Andersson, Kerstin Almroth, Ann-Charlotte Borgefeldt, Britt-Inger 
Dahlin, Christina Danewid, Kristina From, Chatrine Hasselberg, Pernilla Helgesson, 
Helene Krook, Christofer Lagerros, Malin Lindell, Tuomas Mirtti, Annica Nilsson, 
Madeleine Nilsson, Hanna Nyberg, Merja Rignell, Inger Johanne Stokkan, Malin 
Ståhlgren, Øystein Størkersen and the SPCG-17 study group.
Collaborators SPCG-17 study group: Johan Stranne; Jonas Wallström; Pär 
Dahlman; Bengt Friedrich; Conny Ström; Periklis Koumoutsakos; Annika Larsson; 
Mattias Tell; Magnus Alm; Jon Forsberg; Aus Saudi; Ove Andrén; Wolfgang Krauss; 
Hanna Vasarainen; Anu Kenttämies; Sverre Langørgen
Contributors All authors have made the following contributions to the work: 
substantial contributions to the conception or design of the work; or the acquisition, 
analysis or interpretation of data for the work. Drafting the work or revising it 
critically for important intellectual content. Final approval of the version to be 
published. Agreement to be accountable for all aspects of the work in ensuring 
that questions related to the accuracy or integrity of any part of the work are 
appropriately investigated and resolved.
Funding This study was supported by grants from the Swedish Cancer Society 
(2016/466 and 2014/1275), the Swedish Research Council (2016–00177 and 
2016–01293), the Nordic Cancer Union and the Percy Falk Foundation to Dr Bill-
Axelson and the Karolinska Institutet Distinguished Professor Award to Dr Hans-
Olov Adami (2368/10-221).
Competing interests None declared.
Patient consent for publication Not required.
Ethics approval The study has ethical approval from Sweden (the Regional Ethical 
Review Board in Uppsala), Norway (REK Midt—Regional Ethics Committee Central), 
Finland (Ethics Committee of Surgery, Helsinki University Hospital) and UK (East of 
England—Essex Research Ethics Committee).
Provenance and peer review Not commissioned; externally peer reviewed.
data availability statement No data are available.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
rEFErEnCEs
 1. Ferlay JSI, Ervik M, Dikshit R, et al. V1.0, cancer incidence and 
mortality worldwide: IARC CancerBase No. 11. 2013. Lyon, France: 
International Agency for Research on Cancer, 2012.
 2. Klotz L. Prostate cancer overdiagnosis and overtreatment. Curr Opin 
Endocrinol Diabetes Obes 2013;20:204–9.
 3. Klotz LH. Active surveillance for good risk prostate cancer: rationale, 
method, and results. Can J Urol 2005;12(Suppl 2):21–4.
 4. Bruinsma SM, Bangma CH, Carroll PR, et al. Active surveillance for 
prostate cancer: a narrative review of clinical guidelines. Nat Rev Urol 
2016;13:151–67.
 5. Simpkin AJ, Tilling K, Martin RM, et al. Systematic review and 
meta-analysis of factors determining change to radical treatment 
in active surveillance for localized prostate cancer. Eur Urol 
2015;67:993–1005.
 6. Dall'Era MA, Albertsen PC, Bangma C, et al. Active surveillance 
for prostate cancer: a systematic review of the literature. Eur Urol 
2012;62:976–83.
 7. Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy 
or watchful waiting in early prostate cancer. N Engl J Med 
2014;370:932–42.
 8. Wilt TJ, Jones KM, Barry MJ, et al. Follow-Up of prostatectomy 
versus observation for early prostate cancer. N Engl J Med 
2017;377:132–42.
 9. Hamdy FC, Donovan JL, Lane JA, et al. 10-Year outcomes after 
monitoring, surgery, or radiotherapy for localized prostate cancer. N 
Engl J Med 2016;375:1415–24.
copyright.
 o
n
 January 16, 2020 at University of Helsinki. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-027860 on 22 August 2019. Downloaded from 
7Ahlberg MS, et al. BMJ Open 2019;9:e027860. doi:10.1136/bmjopen-2018-027860
Open access
 10. Naji L, Randhawa H, Sohani Z, et al. Digital rectal examination for 
prostate cancer screening in primary care: a systematic review and 
meta-analysis. Ann Fam Med 2018;16:149–54.
 11. Eastham JA, Riedel E, Scardino PT, et al. Variation of serum prostate-
specific antigen levels: an evaluation of year-to-year fluctuations. 
JAMA 2003;289:2695–700.
 12. Berney DM, Algaba F, Camparo P, et al. The reasons behind variation 
in Gleason grading of prostatic biopsies: areas of agreement and 
misconception among 266 European pathologists. Histopathology 
2014;64:405–11.
 13. Loeb S, Folkvaljon Y, Makarov DV, et al. Five-Year nationwide 
follow-up study of active surveillance for prostate cancer. Eur Urol 
2015;67:233–8.
 14. Drost F-JH, Rannikko A, Valdagni R, et al. Can active surveillance 
really reduce the harms of overdiagnosing prostate cancer? A 
reflection of real life clinical practice in the PRIAS study. Transl Androl 
Urol 2018;7:98–105.
 15. Fütterer JJ, Briganti A, De Visschere P, et al. Can clinically significant 
prostate cancer be detected with multiparametric magnetic 
resonance imaging? A systematic review of the literature. Eur Urol 
2015;68:1045–53.
 16. Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS Prostate 
Imaging - Reporting and Data System: 2015, Version 2. Eur Urol 
2016;69:16–40.
 17. Scarpato KR, Barocas DA. Use of mpMRI in active surveillance for 
localized prostate cancer. Urol Oncol 2016;34:320–5.
 18. Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic 
accuracy of multi-parametric MRI and TRUS biopsy in prostate 
cancer (PROMIS): a paired validating confirmatory study. Lancet 
2017;389:815–22.
 19. Distler FA, Radtke JP, Bonekamp D, et al. The value of PSA density 
in combination with PI-RADS™ for the accuracy of prostate cancer 
prediction. J Urol 2017;198:575–82.
 20. Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-Targeted 
or standard biopsy for prostate-cancer diagnosis. N Engl J Med 
Overseas Ed 2018;378:1767–77.
 21. Frye TP, George AK, Kilchevsky A, et al. Magnetic resonance 
Imaging-Transrectal ultrasound guided fusion biopsy to 
detect progression in patients with existing lesions on active 
surveillance for low and intermediate risk prostate cancer. J Urol 
2017;197:640–6.
 22. Klotz L, Loblaw A, Sugar L, et al. Active surveillance magnetic 
resonance imaging study (ASIST): results of a randomized 
multicenter prospective trial. Eur Urol 2019;75:300-309.
 23. Klotz L. Active surveillance for intermediate risk prostate cancer. Curr 
Urol Rep 2017;18:80.
 24. Klotz L, Vesprini D, Sethukavalan P, et al. Long-Term follow-up of a 
large active surveillance cohort of patients with prostate cancer. J 
Clin Oncol 2015;33:272–7.
 25. Musunuru HB, Yamamoto T, Klotz L, et al. Active surveillance 
for intermediate risk prostate cancer: survival outcomes in the 
Sunnybrook experience. J Urol 2016;196:1651–8.
 26. Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG 
guidelines on prostate cancer. Part II: treatment of relapsing, 
metastatic, and castration-resistant prostate cancer. Eur Urol 
2017;71:630–42.
 27. Szymanski KM, Wei JT, Dunn RL, et al. Development and validation 
of an abbreviated version of the expanded prostate cancer index 
composite instrument for measuring health-related quality of life 
among prostate cancer survivors. Urology 2010;76:1245–50.
 28. Danneman D, Drevin L, Robinson D, et al. Gleason inflation 1998-
2011: a registry study of 97,168 men. BJU Int 2015;115:248–55.
 29. Lundström K-J, Drevin L, Carlsson S, et al. Nationwide population 
based study of infections after transrectal ultrasound guided prostate 
biopsy. J Urol 2014;192:1116–22.
 30. Zowawi HM, Harris PNA, Roberts MJ, et al. The emerging threat of 
multidrug-resistant gram-negative bacteria in urology. Nat Rev Urol 
2015;12:570–84.
 31. Bratt O, Carlsson S, Holmberg E, et al. The study of active 
monitoring in Sweden (SAMS): a randomized study comparing two 
different follow-up schedules for active surveillance of low-risk 
prostate cancer. Scand J Urol 2013;47:347–55.
copyright.
 o
n
 January 16, 2020 at University of Helsinki. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-027860 on 22 August 2019. Downloaded from 
